Strategic footprint Medstop is a mid-sized Swedish pharmaceutical chain with 69 pharmacies and a regional focus in medium to large cities in Southern and Central Sweden, extending to Uppsala. This suggests sales opportunities in regional wholesaling, store-level promotions, and pharmacy-supply contracts that target urban catchment areas.

Ownership change The company was acquired by Oriola KD in 2013 and later merged under Kronans Droghandel Apotek AB. This corporate lineage indicates potential alignment with Oriola/Kronans distribution networks, shared supplier programs, and channel partnerships that could be leveraged for co-marketing and product launches.

Revenue scale With reported revenue in the range of 1M to 10M USD, Medstop sits in a smaller-to-mid-market tier among peers, signaling openness to scalable B2B initiatives such as supplier financing, tiered discount structures, and pilot programs for new pharmaceutical products and consumer health lines.

Private equity backing Ownership by Segulah indicates potential strategic investments in growth initiatives, technology upgrades, or network expansions. This could translate to opportunities for capital-efficient partnerships, value-added services, and performance-based collaborations within Medstop’s pharmacy network.

Growth opportunities Medstop’s history of pioneering a private-run pharmacy brand post-monopoly and its regional expansion mindset suggests receptiveness to innovative product categories, digital health tools, and customer engagement programs that can be piloted across its 69 locations and later scaled within the Kronans Droghandel umbrella.